CT P27

Drug Profile

CT P27

Alternative Names: CT-P27; Universal influenza antibody - Celltrion

Latest Information Update: 30 Aug 2016

Price : $50

At a glance

  • Originator Celltrion
  • Class Monoclonal antibodies
  • Mechanism of Action Influenza virus fusion inhibitors; Influenza virus haemagglutinin glycoprotein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Influenza virus infections

Most Recent Events

  • 03 Feb 2016 CT P27 is still in active development
  • 10 Feb 2014 Phase-II clinical trials in Influenza virus infections (In volunteers) in United Kingdom (IV)
  • 18 Nov 2013 Adverse events and pharmacokinetics data from a phase I trial in Volunteers released by Celltrion
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top